Table 1.
Unadjusted Frequency of Hepatitis C virus (HCV) Diagnoses, 2001–2019
| Entire Sample (N=10,507,834) | People who inject drugs (N=5,195) | ||||||
|---|---|---|---|---|---|---|---|
| Gender | n | % | P | Gender | n | % | P |
| TGD | TGD | ||||||
| No HCV | 38,032 | 98.94 | *** | No HCV | 103 | 93.64 | ** |
| HCV | 409 | 1.06 | HCV | 7 | 6.36 | ||
| Cis | Cis | ||||||
| No HCV | 10,430,093 | 99.62 | No HCV | 4,965 | 97.64 | ||
| HCV | 39,300 | 0.38 | HCV | 120 | 2.36 | ||
| Gender Subgroups | n | % | P | Gender Subgroups | n | % | P |
| TFN | TFN | ||||||
| No HCV | 9,755 | 98.14 | *** | No HCV | 24 | 92.31 | ** |
| HCV | 185 | 1.86 | HCV | 2 | 7.69 | ||
| TMN | TMN | ||||||
| No HCV | 18,745 | 99.27 | No HCV | 69 | 95.83 | ||
| HCV | 137 | 0.73 | HCV | 3 | 4.17 | ||
| TGD Un. | TGD Unclassified | ||||||
| No HCV | 9,532 | 99.10 | No HCV | 10 | 83.33 | ||
| HCV | 87 | 0.90 | HCV | 2 | 16.67 | ||
| Cis Women | Cis Women | ||||||
| No HCV | 5,199,428 | 99.70 | No HCV | 2,587 | 98.14 | ||
| HCV | 15,830 | 0.30 | HCV | 49 | 1.86 | ||
| Cis Men | Cis Men | ||||||
| No HCV | 5,228,289 | 99.55 | No HCV | 2,377 | 97.10 | ||
| HCV | 23,461 | 0.45 | HCV | 71 | 2.90 | ||
| Cis Unclassified | Cis Unclassified | ||||||
| No HCV | 2,376 | 99.62 | No HCV | 1 | 100% | ||
| HCV | 9 | 0.38 | HCV | -- | -- | ||
Cis, Cisgender; P, P-value; TGD, Transgender and gender diverse; TFN, Trans feminine and non-binary; TMN, Trans masculine and non-binary. Note: Unadjusted frequency of hepatitis C virus (HCV) diagnoses among entire sample and people who inject drugs stratified by gender in Optum’s de-identified Clinformatics® Data Mart Database from 2001–2019. Race: Asian, Black, and White categories are non-Hispanic. P-values were derived from Fisher’s exact test for gender subgroups among people who inject drugs; χ2 tests were used for all other analyses.
Boldface indicates statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001).